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Hydroquinone is the best studied andmost widely
used topical depigmenting agent, and represents the
gold standard for treatment of disorders of pigmen-
tation. Although ochronosis is a known sequela of
long-term hydroquinone use, pigmentation of the
nails is rarely a reported side effect. We present a case
of identical twins who developed hyperpigmenta-
tion of identical nails after the use of a compounded
cream containing 10% hydroquinone and 0.05%
tretinoin to improve facial dyschromia.CASE REPORT
Sixty-two-year-old identical twin males presented
with hyperpigmentation after the use of hydroqui-
none. Both twins noticed nail dyspigmentation on
their distal fourth and fifth fingernails 3 months after
starting treatment with hydroquinone. In both pa-
tients the hyperpigmentationwas asymptomatic, and
neither had any underlying onychodystrophy. Over
the next 2 months, the brown dyspigmentation
continued to extend proximally eventually
measuring as much as 7 mm on the first patient’s
hand and 9 mm on the second patient’s hand (Figs 1
and 2). At a follow-up visit 2 months later, the nails
for both patients were a dusky brown color. Attempts
to scrape off the pigment were unsuccessful.
Periodic acideSchiff stain was negative, and cultures
showed no growth. Complete blood count and
comprehensive metabolic panel were both within
normal limits.
Both patients were using a mixture of 10% hydro-
quinone and tretinoin 0.05% cream for cosmetic
improvement of facial lentigines. The dyschromia for
both patients improved significantly after twice-daily
use, applied using their fifth digit, for 2 months.
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was thought that hydroquinone was the most likely
causal agent and was therefore discontinued. The
patients were seen again 3 months after stopping the
hydroquinone cream, and the nail dyspigmentation
on both individuals had resolved. One subject
restarted the hydroquinone cream because of the
asymptomatic and cosmetic nature of the nail dys-
pigmentation, and the same nail developed hyper-
pigmentation within 2 months of daily use.DISCUSSION
Fitzpatrick first recognized hydroquinone as a
depigmenting agent in the 1960s.1 Hydroquinone is
known to be a strong inhibitor of melanin produc-
tion, but its mechanism of action is poorly under-
stood. It is proposed that hydroquinone acts as a
structural analog of melanin precursors that inhibits
the conversion of L-DOPA to melanin by tyrosinase.
Hydroquinone also generates free radicals that
further damage melanosomes.2 The paradoxical hy-
perpigmentation of fingernails is a rare phenomenon
seen with hydroquinone use.
Very few cases reported of hydroquinone leading
to hyperpigmentation of nails are reported.3-5 In
these cases, the hyperpigmentation presented as an
asymptomatic darkening of the distal fingernails on a
variable number of nails on one or both hands. The
pigment has been described as chestnut brown and
typically worsened with continued use of hydroqui-
none. Sun exposure may lead to darkening and
expansion of affected areas.5 Pigment changes typi-
cally resolve after cessation of hydroquinone.3-5 In
our case, hyperpigmentation resolved in 3 months.
Hydroquinone is thought to be a safe and
effective cream at low concentrations of 4% or
less and is the gold standard for depigmentingJAAD Case Reports 2016;2:57-8.
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Fig 1. Brown discoloration on the distal medial aspects of
the nails on the fourth and fifth digits of twin A’s hand.
Fig 2. Prominent brown discoloration on the distal medial
aspects of the nails on the fourth and fifth digits of twin B’s
hand.
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concentrations up to 2% in over-the-counter prod-
ucts and up to 4% in prescription creams. Higher
concentrations are available by compounding phar-
macies and over the counter in other countries, but
lower concentrations are typically used because of
an increased potential for irritation and ochronosis.
Although it is the most widely used depigmenting
agent in the United States, that is not the case
throughout the rest of the world where hydroqui-
none’s safety has come into question.6 Although the
most common side effects are typically self-limited,
concerns remain about its potential mutagenicity
and carcinogenicity. In vitro and animal models
have shown DNA damage with use of hydroqui-
none. Animal models have also shown increased
development of leukemia in some studies.7 This led
some countries in Europe and Asia to ban hydro-
quinone over concerns about potential malignancy
risk. Despite these claims, there are no documented
cases of cutaneous or internal malignancy associ-
ated with hydroquinone use in humans.7 Reports of
malignancy in animal models involved oral hydro-
quinone used at very high concentrations, much
higher than those used topically. More than 25
cases of ochronosis were reported since hydroqui-
none’s inception over 50 years ago, with nonedescribing neoplastic induction. These studies show
that there is no evidence that hydroquinone leads
to malignancy when used topically and at low
concentrations. Although nail hyperpigmentation
is a rare side effect, we show here, similar to
previous findings, that it is self-limited. It is impor-
tant for providers to be aware of this potential
complication and to discontinue hydroquinone use
in a timely fashion if identified.
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